AbbVie(ABBV) surged out of the gate following its January 2013 spinoff from Abbott Laboratories(ABT). By December 2014, the stock price had doubled. Since then, however, the stock languished, continuing to trade below its December 2014 highs. Despite efforts to diversify, Humira, which is ...
Dividend Yield:3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, andAbbVie(NYSE:ABBV) is one such bargain. ABBV stock is ...